Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. 1997

M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
University of Athens School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, Greece.

Langerhans-cell histiocytosis (LCH) is a rare condition with a wide clinical spectrum and variable prognosis. Patients with multisystem LCH have been treated with a variety of agents but may develop resistant and progressive disease. Based on a preliminary encouraging report on the activity of 2 chlorodoxyadenosine in this disease, we administered this agent to a patient with LCH which was resistant to corticosteroids and etoposide. After 4 courses of treatment the patient achieved a complete remission which is currently ongoing for 12 months. 2 CdA appears to be effective in patients with resistant LCH and warrants investigation in previously untreated patients with poor risk disease.

UI MeSH Term Description Entries
D005260 Female Females
D006646 Histiocytosis, Langerhans-Cell A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder. Histiocytosis X,Langerhans-Cell Granulomatosis,Langerhans-Cell Histiocytosis,Hand-Schueller-Christian Disease,Hand-Schueller-Christian Syndrome,Hand-Schüller-Christian Disease,Hand-Schüller-Christian Syndrome,Hashimoto-Pritzger Disease,Histiocytosis, Generalized,Histiocytosis-X,Langerhans Cell Granulomatosis,Langerhans Cell Granulomatosis, Pulmonary,Langerhans Cell Histiocytosis,Letterer-Siwe Disease,Non-Lipid Reticuloendotheliosis,Pulmonary Histiocytosis X,Pulmonary Langerhans Cell Granulomatosis,Schueller-Christian Disease,Systemic Aleukemic Reticuloendotheliosis,Type 2 Histiocytosis,Aleukemic Reticuloendothelioses, Systemic,Aleukemic Reticuloendotheliosis, Systemic,Cell Granulomatoses, Langerhans,Cell Granulomatosis, Langerhans,Cell Histiocytoses, Langerhans,Cell Histiocytosis, Langerhans,Disease, Hand-Schueller-Christian,Disease, Hand-Schüller-Christian,Disease, Hashimoto-Pritzger,Disease, Letterer-Siwe,Disease, Schueller-Christian,Diseases, Hashimoto-Pritzger,Generalized Histiocytoses,Generalized Histiocytosis,Granulomatoses, Langerhans Cell,Granulomatosis, Langerhans Cell,Granulomatosis, Langerhans-Cell,Hand Schueller Christian Disease,Hand Schueller Christian Syndrome,Hand Schüller Christian Disease,Hand Schüller Christian Syndrome,Hashimoto Pritzger Disease,Hashimoto-Pritzger Diseases,Histiocytoses, Generalized,Histiocytoses, Langerhans Cell,Histiocytoses, Type 2,Histiocytosis X, Pulmonary,Histiocytosis, Langerhans Cell,Histiocytosis, Type 2,Langerhans Cell Granulomatoses,Langerhans Cell Histiocytoses,Letterer Siwe Disease,Non Lipid Reticuloendotheliosis,Non-Lipid Reticuloendothelioses,Reticuloendothelioses, Non-Lipid,Reticuloendothelioses, Systemic Aleukemic,Reticuloendotheliosis, Non-Lipid,Reticuloendotheliosis, Systemic Aleukemic,Schueller Christian Disease,Syndrome, Hand-Schueller-Christian,Syndrome, Hand-Schüller-Christian,Systemic Aleukemic Reticuloendothelioses,Type 2 Histiocytoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D017338 Cladribine An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. 2-Chloro-2'-deoxyadenosine,2-Chlorodeoxyadenosine,2'-Deoxy-2-chloroadenosine,Leustatin

Related Publications

M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
March 2003, Respirology (Carlton, Vic.),
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
March 2002, American journal of hematology,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
September 2006, Leukemia & lymphoma,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
March 2003, Mayo Clinic proceedings,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
September 1994, Annals of internal medicine,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
January 2001, Pediatric hematology and oncology,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
January 2009, Journal of pediatric hematology/oncology,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
March 2001, Medicina clinica,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
July 2003, Journal of pediatric hematology/oncology,
M A Dimopoulos, and M Theodorakis, and E Kostis, and C Papadimitris, and L A Moulopoulos, and M Anastasiou-Nana
December 2020, British journal of haematology,
Copied contents to your clipboard!